National Core Formulary
The IHS National Core Formulary represents the basic standard of care drugs which must be carried by all federal facilities to generally promote the parity, portability, quality, safety, convenience, and cost-effectiveness of the pharmacy benefit.
- It establishes the "floor" for the pharmacy benefit.
- Except in closed classes, facilities are expected to add other drugs to the local formulary as needed.
Last Updated: 11/24/2021
Search Medications Results
The following is a list of Medications currently in the queue. 204 record(s) found.
| Medication | Pharmacological Category | Formulary Brief | Notes | Similar Medications |
|---|---|---|---|---|
| Acetaminophen | Analgesic, Miscellaneous | |||
| Adalimumab -OR- Etanercept (can choose either product) | Antirheumatic, Disease Modifying; Tumor Necrosis Factor (TNF) Blocking Agent | TNF Inhibitors (2016) | ONLY In consultation with a rheumatologist | Etanercept -OR- Adalimumab (can choose either product) |
| Albuterol nebulized solution | Beta2 Agonist | |||
| Albuterol, metered dose inhaler (MDI) | Beta2 Agonist | NPTC Meeting Update (Nov 2017) | *Any product* | |
| Alendronate | Bisphosphonate Derivative | Osteoporosis (2016) | ||
| Allopurinol | Antigout Agent; Xanthine Oxidase Inhibitor | Gout (2016) | ||
| Alogliptin | Antidiabetic Agent, Dipeptidyl Peptidase 4 (DPP-4) Inhibitor | DPP-IV Inhibitors (2019) | ||
| Amitriptyline | Antidepressant, Tricyclic | Antidepressants in Pain Mgmt (2014) | Nortriptyline | |
| Amlodipine | Antihypertensive; Calcium Channel Blocker, Dihydropyridine | Calcium Channel Blockers (2014) | Diltiazem | |
| Amoxicillin | Antibiotic, Penicillin | Outpatient Abx Stewardship & URIs (2021) | Pediatric and Adult oral formulations | Amoxicillin and Clavulanate; Penicillin G benzathine; Penicllin V potassium |
| Amoxicillin and Clavulanate | Antibiotic, Penicillin | Outpatient Abx Stewardship & URIs (2021) | Pediatric and Adult oral formulations | Amoxicillin; Penicillin G benzathine; Penicllin V potassium |
| Anastrozole | Antineoplastic Agent, Aromatase Inhibitor | |||
| Apixaban | Anticoagulant; Direct Oral Anticoagulant (DOAC); Factor Xa Inhibitor | Direct Oral Anticoagulants (2017) | Warfarin | |
| Aripiprazole lauroxil | Antipsychotic, Atypical (Second Generation) - Injectable | Long-Acting Injectable Antipsychotics (2020) | Injectable | Haloperidol decanoate |
| Aspirin | Antiplatelet Agent; Nonsteroidal Anti-Inflammatory Drug; Salicylate | |||
| Atenolol | Antihypertensive; Beta-Blocker, Beta1 Selective | Beta Blockers (2014) | Metoprolol; Propranolol | |
| Atomoxetine | Norepinephrine Reuptake Inhibitor, Selective | ADHD (2020) | Dextroamphetamine / Amphetamine (immediate release); Dextroamphetamine / Amphetamine (long-acting); Methylphenidate (immediate release); Methylphenidate (long-acting) | |
| Atorvastatin | Antilipemic Agent, HMG-CoA Reductase Inhibitor | Dyslipidemia Guideline Review (2014) | Pravastatin; Rosuvastatin; Simvastatin | |
| Atypical antipsychotic | Antipsychotic, Atypical | Atypical Antipsychotic Agents (2015) | *Any product* | Aripiprazole lauroxil; Haloperidol decanoate |
| Azithromycin | Antibiotic, Macrolide | STIs - PART 1 (2021) | ||
| Benzoyl Peroxide | Topical Skin Product, Acne | Acne Treatment (2020) | Benzoyl Peroxide AND Clindamycin, topical combination | |
| Benzoyl Peroxide AND Clindamycin, topical combination | Topical Skin Product, Acne; Topical Skin Product, Acne (Lincosamide Antibiotic) | Acne Treatment (2020) | Benzoyl Peroxide | |
| Bictegravir/emtricitabine/tenofovir alafenamide | Antiretroviral, Integrase Inhibitor (Anti-HIV) | HIV Treatment (2019) | Dolutegravir/abacavir/lamivudine; Emtricitabine/tenofovir disoproxil fumarate; Raltegravir | |
| Buprenorphine, long-acting (**REMS drug**) | Analgesic, Opioid; Analgesic, Opioid Partial Agonist | MAT for OUD (2021) | Any formulation; Restricted to treatment of Opioid Use Disorder; **See REMS here** | Buprenorphine, short-acting (**REMS drug**); Buprenorphine-naloxone (**REMS drug**) |
| Buprenorphine, short-acting (**REMS drug**) | Analgesic, Opioid; Analgesic, Opioid Partial Agonist | MAT for OUD (2021) | Any formulation; Restricted to treatment of Opioid Use Disorder; **See REMS here** | Buprenorphine, long-acting (**REMS drug**); Buprenorphine-naloxone (**REMS drug**) |
| Buprenorphine-naloxone (**REMS drug**) | Analgesic, Opioid; Analgesic, Opioid Partial Agonist | Opioid Use Disorder (2018) | **See REMS here** | Naloxone |
| Bupropion | Antidepressant, Dopamine/Norepinephrine-Reuptake Inhibitor; Smoking Cessation Aid | Nicotine Dependence (2015) | Varenicline; Venlafaxine | |
| Calcium | Electrolyte supplement | *Any formulation* | ||
| Carbamazepine | Anticonvulsant, Miscellaneous | Antiepileptics (2014) | Divalproex; Lamotrigine; Levetiracetam; Phenytoin; Topiramate | |
| Carbidopa-Levodopa (immediate release) | Anti-Parkinson Agent; Decarboxylase Inhibitor-Dopamine Precursor | Parkinson's Disease (2019) | ||
| Carvedilol | Antihypertensive; Beta-Blocker with Alpha-Blocking Activity | Beta-blockers in Heart Failure (2017) | *Immediate-release only | Atenolol; Metoprolol; Propranolol |
| Cefdinir | Antibiotic, Cephalosporin (Third Generation) | Outpatient Abx Stewardship & URIs (2021) | Pediatric and Adult oral formulations | Cefixime; Ceftriaxone Injection; Cephalexin |
| Cefixime | Antibiotic, Cephalosporin (Third Generation) | STIs - PART 1 (2021) | For outpatient treatment of gonorrhea for Expedited Partner Therapy or when injection therapy is not possible | Cefdinir; Ceftriaxone Injection; Cephalexin |
| Ceftriaxone Injection | Antibiotic, Cephalosporin (Third Generation) | STIs - PART 1 (2021) | Cefdinir; Cefixime; Cephalexin | |
| Cephalexin | Antibiotic, Cephalosporin (First Generation) | Outpatient Abx Stewardship & URIs (2021) | Pediatric and Adult oral formulations | Cefdinir; Cefixime; Ceftriaxone Injection |
| Chlorthalidone | Antihypertensive; Thiazide-Related Diuretic | Diuretic Agents (2014) | Hydrochlorothiazide | |
| Citalopram | Antidepressant, Selective Serotonin Reuptake Inhibitor | SSRIs (2019) | Escitalopram; Fluoxetine; Paroxetine; Sertraline | |
| Clindamycin | Antibiotic, Lincosamide | Outpatient Abx Stewardship & URIs (2021) | Pediatric and Adult oral formulations | |
| Clonazepam | Benzodiazepine | Alcohol Withdrawal Syndrome (2015) | Lorazepam | |
| Clopidogrel | Antiplatelet Agent | Antiplatelets (2015) | Aspirin | |
| Corticosteriods (Topical) - High potency (Class I and II) | Topical Corticosteroids | Psoriasis (2018) | Corticosteroid (Topical) - Intermediate potency; Corticosteroid (Topical) - Low potency | |
| Corticosteroid (Topical) - Intermediate potency | Topical Corticosteroids | *Any product* | Corticosteriods (Topical) - High potency (Class I and II); Corticosteroid (Topical) - Low potency | |
| Corticosteroid (Topical) - Low potency | Topical Corticosteroids | *Any product* | Corticosteriods (Topical) - High potency (Class I and II); Corticosteroid (Topical) - Intermediate potency | |
| Corticosteroid, intranasal | Intranasal Corticosteroid | *Any product* | ||
| Cyanocobalamin (Vitamin B12), oral | Vitamin, Water Soluble | Hematologic Supplements (2016) | ||
| Dextroamphetamine / Amphetamine (immediate release) | Central Nervous System Stimulant | Pediatric use only | Dextroamphetamine and amphetamine (long-acting) | |
| Dextroamphetamine / Amphetamine (long-acting) | Central Nervous System Stimulant | Pediatric use only | Dextroamphetamine and amphetamine (immediate release) | |
| Diclofenac | Nonsteroidal Anti-Inflammatory Drug | NSAIDs (2014) | *Any formulation* | Ibuprofen; Indomethacin; Meloxicam; Naproxen |
| Dicyclomine | Anticholinergic Agent | Irritable Bowel Syndrome (2018) | ||
| Digoxin | Antiarrhythmic Agent, Miscellaneous; Cardiac Glycoside | Digoxin Use (2016) | ||
| Diltiazem | Antihypertensive; Calcium Channel Blocker, Nondihydropyridine | Calcium Channel Blockers (2014) | Amlodipine | |
| Divalproex | Anticonvulsant, Miscellaneous | ER Lithium & Divalproex (2012) | Carbamazepine; Lamotrigine; Levetiracetam; Phenytoin; Topiramate | |
| Dolutegravir | Antiretroviral, Integrase Inhibitor (Anti-HIV) | HIV Updates (2020) | For HIV treatment in pregnant patients | Emtricitabine/tenofovir disoproxil fumarate; Raltegravir |
| Dolutegravir/abacavir/lamivudine | Antiretroviral, Integrase Inhibitor (Anti-HIV) | HIV Treatment (2019) | *Note: HLA B5701 testing required prior to initiation | Bictegravir/emtricitabine/tenofovir alafenamide; Dolutegravir; Emtricitabine/tenofovir disoproxil fumarate; Raltegravir |
| Donepezil | Acetylcholinesterase Inhibitor (Central) | 5mg and 10mg strengths | ||
| Doxazosin | Alpha1 Blocker; Antihypertensive | Benign Prostatic Hypertrophy (2016) | Prazosin; Tamsulosin | |
| Doxycycline | Antibiotic, Tetracycline | STIs - PART 1 (2021) | ||
| Duloxetine | Antidepressant, Serotonin/Norepinephrine Reuptake Inhibitor/Antagonist | Diabetic Neuropathy (2018) | Bupropion; Venlafaxine | |
| Empagliflozin | Antidiabetic Agent, Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor | SGLT-2 Inhibitors (2019) | ||
| Emtricitabine/tenofovir disoproxil fumarate | Antiretroviral, Reverse Transcriptase Inhibitor, Nucleoside (Anti-HIV); Antiretroviral, Reverse Transcriptase Inhibitor, Nucleotide (Anti-HIV) | HIV Pre-Exposure Prophylaxis (PrEP) (2018) | For (1) Pre-Exposure HIV Prophylaxis, (2) Post-Exposure HIV Prophylaxis (with raltegravir) or (3) HIV Treatment (with raltegravir) in patients with contraindications for 1st line anti-HIV agents | Raltegravir |
| Epinephrine Injection Devices (both 0.15mg and 0.3mg) | Alpha-/Beta- Agonist | Epinephrine Injection Devices (2020 | Any device, auto-injector or pre-filled syringe | |
| Escitalopram | Antidepressant, Selective Serotonin Reuptake Inhibitor | SSRIs (2019) | Citalopram; Fluoxetine; Paroxetine; Sertraline | |
| Estradiol tablets | Estrogen Derivative | Menopausal Hormone Therapy (2016) | ||
| Estrogen vaginal cream | Estrogen Derivative | NPTC Meeting Update (May 2018) | *Any product* | Estradiol tablets |
| Etanercept -OR- Adalimumab (can choose either product) | Antirheumatic, Disease Modifying; Tumor Necrosis Factor (TNF) Blocking Agent | TNF Inhibitors (2016) | ONLY In consultation with a rheumatologist | Adalimumab -OR- Etanercept (can choose either product) |
| Ethambutol | Antitubercular Agent | Isoniazid; Pyrazinamide; Rifampin; Rifapentine | ||
| Ethinyl estradiol / Etonogestrel vaginal ring | Contraceptive; Estrogen and Progestin Combination | Contraception (2016) | ||
| Ethinyl estradiol / Norelgestromin, transdermal | Contraceptive; Estrogen and Progestin Combination | Contraception (2016) | ||
| Ethosuximide | Anticonvulsant, Succinimide | Anti-Seizure Drugs (2021) | Carbamazepine; Clonazepam; Divalproex; Gabapentin; Lamotrigine; Levetiracetam; Phenytoin; Topiramate | |
| Etonogestrel, implant | Contraceptive; Progestin | Contraception (2016) | For use by a skilled and privileged provider | Oral contraceptive pill, progestin only |
| Ezetimibe | Antilipemic Agent, 2-Azetidinone | 2018 ACC/AHA Cholesterol Guidelines (2019) | ||
| Finasteride | 5 Alpha-Reductase Inhibitor | Benign Prostatic Hypertrophy (2016) | ||
| Fluoride, oral | Nutritional Supplement | Supplements in Oral Health (2016) | *Any oral formulation* | |
| Fluoxetine | Antidepressant, Selective Serotonin Reuptake Inhibitor | Sertraline | ||
| Fluticasone/salmeterol | Beta2 Agonist, Long-Acting; Corticosteroid, Inhalant | LABAs (2019) | Mometasone (Asmanex®) | |
| Folic Acid | Vitamin, Water Soluble | Supplements in Womens Health (2016) | Any product containing >400 mcg / daily dose | |
| Furosemide | Antihypertensive; Loop Diuretic | Heart Failure Overview (2017) | ||
| Gabapentin | Anticonvulsant, Miscellaneous; GABA Analog | Gabapentin & Pregabalin in Pain (2014) | ||
| Glecaprevir/pibrentasvir (Mavyret®) | Antihepaciviral | HCV Treatment (2018) | Ledipasvir/sofosbuvir (Harvoni®); Sofosbuvir/velpatasvir (Epclusa®) | |
| Glipizide | Antidiabetic Agent; Sulfonylurea | Sulfonylureas (2015) | ||
| Glucagon | Antidote; Hypoglycemia | For outpatient use | ||
| Glucose, Oral | Antidote | Glucagon Delivery Devices (2021) | Any formulation | Glucagon |
| H1 Antagonist (2nd generation), long-acting | Histamine H1 Antagonist, Second Generation | *Any product* | ||
| Haloperidol decanoate | Antipsychotic, Typical (First Generation) - Injectable | Long-Acting Injectable Antipsychotics (2020) | Injectable | Aripiprazole lauroxil |
| Hydrochlorothiazide | Antihypertensive; Thiazide Diuretic | Diuretics (2014) | Chlorthalidone | |
| Hydroxychloroquine | Antimalarial | Non-biologic DMARDs (2016) | Leflunomide; Methotrexate; Sulfasalazine | |
| Hydroxyzine | Histamine H1 Antagonist, First Generation | Anxiety Disorders (2021) | ||
| Ibuprofen | Nonsteroidal Anti-Inflammatory Drug | NSAIDs (2014) | Diclofenac; Indomethacin; Meloxicam; Naproxen | |
| Indomethacin | Nonsteroidal Anti-Inflammatory Drug | NSAIDs (2014) | Diclofenac; Ibuprofen; Meloxicam; Naproxen | |
| Insulin aspart (NovoLog®) | Insulin, Rapid-Acting | Insulins (2015) | *Branded product*; Pen Device | |
| Insulin aspart / Insulin aspart protamine (NovoLog® Mix 70/30) | Insulin, Combination (70/30 Mix) | Insulins (2015) | *Branded product*; Pen Device | |
| Insulin detemir (Levemir®) | Insulin, Long-Acting | Insulins (2015) | *Branded product*; Pen Device | Insulin glargine, any "interchangeable" product (Semglee® -OR- Lantus®) |
| Insulin glargine, any | Insulin, Long-Acting | Long-Acting Insulins & Biosimilars (2021) | An interchangeable biosimilar product is a biosimilar that meets additional requirements outlined by the law that allows for the FDA to approve biosimilar and interchangeable biosimilar medications. | Insulin detemir (Levemir®) |
| Insulin NPH (NovoLIN® N) | Insulin, Intermediate-Acting | Insulins (2015) | *Branded product* | |
| Insulin NPH / Regular human insulin (NovoLIN® 70/30) | Insulin, Combination (70/30 Mix) | Insulins (2015) | *Branded product* | |
| Insulin Regular human (NovoLIN® R) | Insulin, Short-Acting | Insulins (2015) | *Branded product* | |
| Intrauterine device, copper | Contraceptive | Contraception (2016) | *Any product*; For use by a skilled and privileged provider | Intrauterine device, levonorgestrel |
| Intrauterine device, levonorgestrel | Contraceptive, Progestin | Contraception (2016) | *Any product*; For use by a skilled and privileged provider | Intrauterine device, copper |
| Iron, oral | Iron Salt | Hematologic Supplements (2016) | *Any oral formulation* | |
| Isoniazid | Antitubercular Agent | Ethambutol; Pyrazinamide; Rifampin; Rifapentine | ||
| Isosorbide mononitrate | Antianginal Agent; Vasodilator | Nitroglycerin 0.4 Milligrams; Sublingual; Nitroglycerin patch | ||
| Lactulose | Ammonium Detoxicant; Laxative, Osmotic | Cirrhosis & Complications (2015) | Polyethylene glycol | |
| Lamotrigine | Anticonvulsant, Miscellaneous | Antiepileptics (2014) | Carbamazepine; Divalproex; Levetiracetam; Phenytoin; Topiramate | |
| Laxative, bulk-forming | Bulk-forming Laxative | *Any product* | ||
| Laxative, stimulant | Stimulant Laxative | *Any product* | ||
| Ledipasvir/sofosbuvir (Harvoni®) | Antihepaciviral | HCV Treatment (2018) | Glecaprevir/pibrentasvir (Mavyret®); Sofosbuvir/velpatasvir (Epclusa®) | |
| Leflunomide | Antirheumatic, Disease Modifying | Non-biologic DMARDs (2016) | Hydroxychloroquine; Methotrexate; Sulfasalazine | |
| Letrozole | Antineoplastic Agent, Aromatase Inhibitor | |||
| Levetiracetam | Anticonvulsant, Miscellaneous | Antiepileptics (2014) | Carbamazepine; Divalproex; Lamotrigine; Phenytoin; Topiramate | |
| Levonorgestrel (Plan B One-Step®) | Contraceptive, Progestin | Contraception (2016) | *Branded product* | Ulipristal |
| Levothyroxine | Thyroid Agent | |||
| Liraglutide or semaglutide | Antidiabetic Agent, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist | GLP-1 Receptor Agonists (2019) | Select either of these subcutaneous agents, no preference given | |
| Lisinopril | Antihypertensive, Angiotensin-Converting Enzyme Inhibitor | ACEIs & ARBs in Heart Failure (2017) | ||
| Lithium | Antimanic Agent | ER Lithium & Divalproex (2012) | ||
| Loperamide | Antidiarrheal | Irritable Bowel Syndrome (2018) | ||
| Lorazepam | Benzodiazepine | Alcohol Withdrawal Syndrome (2015) | Clonazepam | |
| Losartan | Antihypertensive, Angiotensin II Receptor Blocker | ACEIs & ARBs in Heart Failure (2017) | ||
| Low-molecular weight heparin | Low-molecular Weight Heparin | VTE Prophylaxis (2011) | *Any product* | |
| Medroxyprogesterone acetate, injection | Contraceptive, Progestin (Injection/Depot) | Contraception (2016) | Medroxyprogesterone, oral; Oral contraceptive pill, progestin only | |
| Medroxyprogesterone, oral | Contraceptive; Progestin | Polycystic Ovarian Syndrome (2017) | Medroxyprogesterone acetate, injection; Oral contraceptive pill, progestin only | |
| Meloxicam | Nonsteroidal Anti-Inflammatory Drug | NSAIDs (2014) | Diclofenac; Ibuprofen; Indomethacin; Naproxen | |
| Memantine | N-Methyl-D-Aspartate (NMDA) Receptor Antagonist | |||
| Metformin | Antidiabetic Agent; Biguanide | |||
| Methimazole | Antithyroid Agent; Thioamide | Hyperthyroidism (2021) | Propylthiouracil | |
| Methotrexate | Antineoplastic Agent; Antirheumatic; Disease Modifying; Immunosuppresant Agent | Non-biologic DMARDs (2016) | Hydroxychloroquine; Leflunomide; Sulfasalazine | |
| Methylphenidate (immediate release) | Central Nervous System Stimulant | Pediatric use only | Methylphenidate (long-acting) | |
| Methylphenidate (long-acting) | Central Nervous System Stimulant | Pediatric use only | Methylphenidate (immediate release) | |
| Metoprolol | Antihypertensive; Beta-Blocker, Beta1 Selective | Beta-blockers in Heart Failure (2017) | Atenolol; Propranolol | |
| Metronidazole | Antibiotic, Miscellaneous | 2021 CDC Guidelines for Sexually Transmitted Infections (2021) | Tinidazole | |
| Moisturizers (both cream- AND petroleum-based) | Skin and Mucous Membrane Agent, Miscellaneous; Topical Skin Product | Atopic Dermatitis (2020) | Corticosteriods (Topical) - High potency (Class I and II); Corticosteroid (Topical) - Intermediate potency; Corticosteroid (Topical) - Low potency; Tacrolimus | |
| Mometasone (Asmanex®) | Corticosteroid, Inhalant | *Branded product* | ||
| Montelukast | Leukotriene Receptor Antagonist | |||
| Mupirocin | Antibiotic, Topical | Skin & Soft Tissue Infections (2021) | ||
| Naloxone | Antidote; Opioid Antagonist | Treatment of Opioid Overdose (2014) | ||
| Naltrexone, extended-release for injection (**REMS drug**) | Antidote; Opioid Antagonist | Opioid Use Disorder (2018) | **See REMS here** | |
| Naltrexone, oral | Antidote; Opioid Antagonist | Alcohol Use Disorders (2015) | Naloxone | |
| Naproxen | Nonsteroidal Anti-Inflammatory Drug | NSAIDs (2014) | Diclofenac; Ibuprofen; Indomethacin | |
| Nicotine replacement therapy (NRT), combination | Smoking Cessation Aid | Nicotine Dependence (2015) | Combination NRT (nicotine patches + any short-acting NRT product) | Bupropion; Varenicline |
| Nitrofurantoin | Antibiotic, Miscellaneous | Urinary Tract Infections (2021) | ||
| Nitroglycerin 0.4 milligrams, sublingual | Antianginal Agent; Antidote, Extravasation; Vasodilator | Isosorbide mononitrate; Nitroglycerin patch | ||
| Nitroglycerin patch | Antianginal Agent; Antidote, Extravasation; Vasodilator | Isosorbide mononitrate; Nitroglycerin 0.4 milligrams; Sublingual | ||
| Nortriptyline | Antidepressant, Tricyclic | Antidepressants in Pain Mgmt (2014) | Amitriptyline | |
| Ondansetron | Antiemetic; Selective 5-HT3 Receptor Antagonist | Antiemetic Agents (2021) | ||
| Ophthalmic Prostaglandin Analog | Ophthalmic Prostaglandin Analog | Ophth Prostaglandin Analogs (2018) | *Any product* | |
| Oral contraceptive pill, extended cycle | Contraceptive | Contraception (2016) | *Any product* | |
| Oral contraceptive pill, monophasic: 20mcg EE (low) | Contraceptive | *Any product* | Monophasic: 30-35mcg EE (medium); Oral contraceptive pill | |
| Oral contraceptive pill, monophasic: 30-35mcg EE (medium) | Contraceptive | *Any product* | Monophasic: 20mcg EE (low) ; Oral contraceptive pill | |
| Oral contraceptive pill, progestin only | Contraceptive | *Any product* | Etonogestrel; Implant; Intrauterine Device; Levonorgestrel | |
| Oral contraceptive pill, triphasic | Contraceptive | *Any product* | Monophasics ; Oral Contraceptive Pill | |
| Oseltamivir | Antiviral Agent; Neuraminidase Inhibitor | Treatment of Influenza (2019) | ||
| Oxcarbazepine | Anticonvulsant, Miscellaneous | Anti-Seizure Drugs (2021) | Carbamazepine; Clonazepam; Divalproex; Gabapentin; Lamotrigine; Levetiracetam; Phenytoin; Topiramate | |
| Oxybutynin, Extended-release | Antispasmodic Agent, Urinary | Antimuscarinics (2019) | Oxybutynin, Immediate-release | |
| Oxybutynin, Immediate-release | Antispasmodic Agent, Urinary | Antimuscarinics (2019) | Oxybutynin, Extended-release | |
| Paroxetine | Antidepressant, Selective Serotonin Reuptake Inhibitor | SSRIs (2019) | Citalopram; Escitalopram; Fluoxetine; Sertraline | |
| Penicillin G benzathine | Antibiotic, Penicillin | STIs - PART 1 (2021) | Amoxicillin; Amoxicillin and Clavulanate; Penicllin V potassium | |
| Penicllin V potassium | Antibiotic, Penicillin | Outpatient Abx Stewardship & URIs (2021) | Pediatric and Adult oral formulations | Amoxicillin; Amoxicillin and Clavulanate; Penicillin G benzathine |
| Phentermine | Central Nervous System Stimulant | Obesity Treatment (2018) | ||
| Phenytoin | Anticonvulsant, Hydantoin | Antiepileptics (2014) | Carbamazepine; Divalproex; Lamotrigine; Levetiracetam; Topiramate | |
| Phosphodiesterase 5 (PDE5) Inhibitor | Phosphodiesterase-5 Enzyme Inhibitor | Phosphodiesterase 5 Inhibitors (2018) | *Any product* | |
| Pioglitazone | Antidiabetic Agent, Thiazolidinedione | Thiazolidinediones (2017) | ||
| Polyethylene glycol | Laxative, Osmotic | Irritable Bowel Syndrome (2018) | *Any product* | Lactulose |
| Pramipexole | Anti-Parkinson Agent, Dopamine Agonist | Insomnia/Sleep Medications (2021) | ||
| Pravastatin | Antilipemic Agent, HMG-CoA Reductase Inhibitor | Hyperlipidemia (2017) | Atorvastatin; Rosuvastatin; Simvastatin | |
| Prazosin | Alpha1 Blocker; Antihypertensive | PTSD Indication (2012) | Doxazosin; Tamsulosin | |
| Prednisone | Corticosteroid, Systemic | |||
| Prenatal Multivitamin | Vitamin | Pregnancy & Prenatal Care (2021) | Must contain >400 mcg of folic acid/dose | |
| Propranolol | Antihypertensive; Beta-Blocker, Non-Selective | Beta Blockers (2014) | Atenolol; Metoprolol | |
| Propylthiouracil | Antithyroid Agent; Thioamide | Hyperthyroidism (2021) | Methimazole | |
| Proton Pump Inhibitor | Proton Pump Inhibitor | GERD & PUD (2018) | *Any product* | |
| Pyrazinamide | Antitubercular Agent | Ethambutol; Isoniazid; Rfapentine ; Rifampin | ||
| Pyridoxine (Vitamin B6) | Vitamin, Water Soluble | Supplements in Obstetrics (2016) | ||
| Raltegravir | Antiretroviral, Integrase Inhibitor (Anti-HIV) | HIV Treatment (2019) | For (1) HIV Post-Exposure Prophylaxis (with emtricitabine/ tenofovir DF) or (2) HIV Treatment (with emtricitabine/tenofovir DF) in patients with contraindications for 1st line anti-HIV agents | Emtricitabine/tenofovir disoproxil fumarate |
| Ranitidine* | Histamine H2 Antagonist | GERD & PUD (2018) | *(April 1, 2020) The Food and Drug Administration has recommended that all formulations of ranitidine be taken off the market due to contaminates of N-Nitrosodimethylamine (NDMA), a carcinogen, in ranitidine products. | Proton Pump Inhibitor |
| Rifampin | Antitubercular Agent | Ethambutol; Isoniazid; Pyrazinamide; Rifapentine | ||
| Rifapentine | Antitubercular Agent | Rifapentine (2013) | Ethambutol; Isoniazid; Pyrazinamide; Rifampin | |
| Rifaximin | Antibiotic, Rifamycin | Hepatic Encephalopathy (2020) | After failure of, or intolerance to, lactulose monotherapy as indicated for hepatic encephalopathy | Lactulose |
| Rosuvastatin | Antilipemic Agent, HMG-CoA Reductase Inhibitor | Hyperlipidemia (2017) | Atorvastatin; Pravastatin; Simvastatin | |
| Salsalate | Salicylate | |||
| Semaglutide or liraglutide | Antidiabetic Agent, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist | GLP-1 Receptor Agonists (2019) | Select either of these subcutaneous agents, no preference given | |
| Serotonin 5-HT1 agonist (Triptan) | Antimigraine Agent; Serotonin 5-HT 1B/1D Receptor Agonist | Triptans (2016) | Any two (2) triptan medications are required, one must be sumatriptan | Sumatriptan |
| Sertraline | Antidepressant, Selective Serotonin Reuptake Inhibitor | Citalopram; Escitalopram; Fluoxetine; Paroxetine | ||
| Sevelamer carbonate | Phosphate Binder | Phosphate Binders (2018) | For patients on dialysis who cannot use calcium-based phosphate binders due to hypercalcemia | Calcium |
| Simvastatin | Antilipemic Agent, HMG-CoA Reductase Inhibitor | Dyslipidemia Guideline Review (2014) | Atorvastatin; Pravastatin; Rosuvastatin | |
| Sofosbuvir/velpatasvir (Epclusa®) | Antihepaciviral | HCV Treatment (2018) | Glecaprevir/pibrentasvir (Mavyret®); Ledipasvir/sofosbuvir (Harvoni®) | |
| Spironolactone | Antihypertensive; Mineralocorticoid Receptor Antagonists; Potassium Sparing Diuretic | Mineralocorticoid Receptor Antagonist in HF (2017) | ||
| Sulfasalazine | 5-Aminosalicylic Acid Derivative | Hydroxychloroquine; Leflunomide; Methotrexate | ||
| Sumatriptan | Antimigraine Agent; Serotonin 5-HT 1B/1D Receptor Agonist | Triptans (2016) | Any two (2) triptan medications are required, one must be sumatriptan | |
| Tacrolimus | Calcineurin Inhibitor; Immunosuppressant Agent; Topical Skin Product | Atopic Dermatitis (2020) | Corticosteriods (Topical) - High potency (Class I and II); Corticosteroid (Topical) - Intermediate potency; Corticosteroid (Topical) - Low potency; Moisturizers (both cream- AND petroleum-based) | |
| Tamoxifen | Antineoplastic Agent, Estrogen Receptor Antagonist; Selective Estrogen Receptor Modulator | |||
| Tamsulosin | Alpha1 Blocker | Benign Prostatic Hypertrophy (2016) | Doxazosin; Prazosin | |
| Tinidazole | Antibiotic, Miscellaneous | 2021 CDC Guidelines for Sexually Transmitted Infections (2021) | Metronidazole | |
| Tiotropium (Spiriva®) | Long-Acting Anticholinergic Agent | Inhaled Anticholinergics (2011) | *Branded product* | |
| Topiramate | Anticonvulsant, Miscellaneous | Antiepileptic Medications (2014) | Carbamazepine; Divalproex; Lamotrigine; Levetiracetam; Phenytoin | |
| Tretinoin, topical | Topical Skin Product, Acne | Acne (2013) | *Any product* | |
| Trimethoprim-sulfamethoxazole | Antibiotic, Miscellaneous | Skin & Soft Tissue Infections (2021) | ||
| Ulipristal | Contraceptive; Progestin Receptor Modulator | Contraception (2016) | Levonorgestrel (Plan B One-Step®) | |
| Umeclidinium/vilanterol | Long-Acting Muscarinic Antagonist (LAMA) / Long-Acting Beta2 Agonist (LABA) | LAMAs (2019) | Tiotropium (Spiriva®) | |
| Vaccines, All ACIP-recommended | Vaccines | Vaccine (2011) | All ACIP recommended vaccines for routine use in accordance with ACIP guidelines | |
| Valacyclovir | Antiviral Agent, Oral | 2021 CDC Guidelines for Sexually Transmitted Infections (2021) | ||
| Varenicline | Partial Nicotine Agonist, Smoking Cessation Aid | Nicotine Dependence (2015) | Bupropion | |
| Venlafaxine | Antidepressant, Serotonin/Norepinephrine Reuptake Inhibitor/Antagonist | SNRIs (2012) | Bupropion; Duloxetine | |
| Vitamin D | Vitamin D Analog | Vitamin D (2010) | *Any product* | |
| Vitamin D Analog (Topical) | Vitamin D Analog | Psoriasis (2018) | *Any product* | |
| Warfarin | Anticoagulant; Vitamin K Antagonist | Direct Oral Anticoagulants (2017) | Apixaban; Low-molecular weight heparin |
